Skip to main content

Navigation principale

  • About
  • Team
  • Portfolio
  • Strategy
  • ESG
  • Testimonials
  • News
  • Contact

Secondary Navigation

  • Fr
  • En

News

You are here

  • Home
  • News
iTeos

iTeos Therapeutics, spin-off of UCLouvain, generates enthusiasm of U.S. investors

Post date
01/04/2020

Walloon biotech iTeos Therapeutics completes a new round of $125 million with historical investors and 5 new leading U.S. funds active in initial public offering (IPO). This is one of the largest

Read more
Promethera

Promethera® announces changes in management team

Post date
30/03/2020

As of February 21st, Prof. Etienne Sokal, M.D., Ph.D., has stepped back from his operational role as Group CMO and will transition to the position of Chairman of Promethera®’s Scientific & Medical

Read more
ViroVet

ViroVet to support COVID19 research and sample testing

Post date
23/03/2020

Belgian biotechnology company ViroVet announced today that it has made its expertise, research staff as well as part of its research facility available to support COVID19 research and sample testing

Read more
iTeos

iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers

Post date
27/02/2020

Initial clinical data expected in 1H 2021

Cambridge, MA and Gosselies, Belgium – February 27, 2020 – iTeos Therapeutics Inc., a privately-held clinical-stage biotechnology company developing

Read more
Promethera

Potentially pivotal trial for industry’s most-advanced cell-based therapy in severe liver diseases expected to generate results in H2 2023

Post date
08/01/2020

Potentially pivotal trial for industry’s most-advanced cell-based therapy in severe liver diseases expected to generate results in H2 2023

Mont-Saint-Guibert, Belgium, and Tokyo, Japan, January 8th

Read more
Syndesi

Syndesi Therapeutics announces the expansion of its management team with the appointment of Torsten Madsen, MD, PhD as Chief Medical Officer.

Post date
19/12/2019

Belgium – 19 December 2019 – Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment,

Read more
Promethera

Promethera Attracts Sony Innovation Fund by IGV and Pegasus Tech Ventures as New Investors in Final Closing of Series D

Post date
16/12/2019

Total amount raised in the Series D reaches €47.2 Million.

Mont-Saint-Guibert, Belgium, and Tokyo, Japan, December 16, 2019 – Promethera® Biosciences SA, a global innovator in cell-based medicines

Read more
iTeos

iTeos Therapeutics Announces Collaboration with Merck Investigating the Combination of its A2A Antagonist with KeytrudaⓇ

Post date
12/12/2019

Study will evaluate the safety and efficacy of the combination of iTeos’ EOS100850 and Merck’s KEYTRUDA® (pembrolizumab)

 

Gosselies, Belgium and Cambridge, MA – Dec. 12, 2019 – iTeos Therapeutics

Read more
Promethera

Notice of Business Alliance between Promethera Biosciences SA and MEDIPAL HOLDINGS

Post date
14/11/2019

 - Bringing Innovative Liver-Focused Cell therapies to Japanese Markets -

Promethera® Biosciences SA (“Promethera®”) and MEDIPAL HOLDINGS CORPORATION (“MEDIPAL”) today announced that they have

Read more
Syndesi Therapeutics

Syndesi Therapeutics announces successful completion of first-in-human Phase I study of novel SV2A modulator, SDI-118, in development for the treatment of cognitive impairment.

Post date
05/12/2019

Belgium – 5 November 2019 – Syndesi Therapeutics SA, a biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment, today announced

Read more
Novadip Biosciences

Novadip Biosciences Presents Clinical Case Study on Next Generation Tissue Regeneration Therapy for Critical Size Bone Reconstruction at EORS Conference

Post date
02/10/2019

Study highlights potential benefit in rare pediatric orthopedic disorder

Mont-Saint-Guibert, Belgium, October 2, 2019 : Novadip Biosciences (“Novadip” or “the company”), a clinical-stage

Read more
Tessares

GO Malta provides innovative services using hybrid fixed and mobile converged solution

Post date
13/09/2019

GO plc in Malta has launched a converged fixed and mobile solution using Tessares’s Multipath TCP technology.  Available to all GO plc customers, this solution combines the operator's fixed network

Read more

Pagination

  • First page « First
  • Previous page ‹‹
  • Page 1
  • Page 2
  • Page 3
  • Current page 4
  • Page 5
  • Next page ››
  • Last page Last »
 

VIVES Funds

VIVES Funds
Bâtiment Le Parc
Place de l’Université 16 bte 27
1348 Louvain-la-Neuve
Belgium

Email
info@sopartec.com
Téléphone
+32 (0)10.39.00.21
Fax
+32 (0)10.39.00.29
Fichier Plan d'accès

Contact

Maximum 5 files.
64 MB limit.
Allowed types: txt rtf pdf doc docx odt ppt pptx odp xls xlsx ods.
Read the general policy of protection of personal data.

VIVES is a multi-sector technology fund that invests in spin-offs from UCLouvain and start-ups in Belgium and neighboring countries. The fund has the ability to invest at different stages of a company's development: seed, start-up and growth.

Menu Pied de page

  • Privacy policy & cookies
  • Terms & conditions
  • © 2023 VIVES fund All rights reserved.
  • Website by Visible